{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:43Z","timestamp":1792039603625,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012781","name":"MSD KK","doi-asserted-by":"publisher","award":["59781"],"award-info":[{"award-number":["59781"]}],"id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109640","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:08Z","timestamp":1790723588000},"page":"109640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC"],"prefix":"10.1016","volume":"221","author":[{"given":"Yuta","family":"Hirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Yagishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-4184","authenticated-orcid":false,"given":"Yuki","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-7303","authenticated-orcid":false,"given":"Yu","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109640_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"7689","key":"10.1016\/j.lungcan.2026.109640_b0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109640_b0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2026.109640_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194846","article-title":"Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for patients with Advanced NSCLC-Real World Efficacy","volume":"13","author":"Mouritzen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109640_b0025","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"10.1016\/j.lungcan.2026.109640_b0030","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109640_b0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109640_b0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1470-2045(24)00040-8","article-title":"Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis","volume":"25","author":"Goulart","year":"2024","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109640_b0045","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109640_b0050","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109640_b0055","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0060","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J Extracell Vesicles."},{"issue":"6478","key":"10.1016\/j.lungcan.2026.109640_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109640_b0070","first-page":"1390","article-title":"The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer","volume":"54","author":"Wang","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109640_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020099","article-title":"Biology, Pathophysiological Role, and Clinical Implications of Exosomes: a critical Appraisal","volume":"8","author":"Jan","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109640_b0080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41571-018-0036-9","article-title":"Extracellular vesicles in cancer - implications for future improvements in cancer care","volume":"15","author":"Xu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7718","key":"10.1016\/j.lungcan.2026.109640_b0085","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109640_b0090","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2026.109640_b0095","unstructured":"Dako. PD-L1 IHC 22C3 pharmDx: interpretation manual. [Available from: https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29158_pd-l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109640_b0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nprot.2017.147","article-title":"Proteome-wide identification of ubiquitin interactions using UbIA-MS","volume":"13","author":"Zhang","year":"2018","journal-title":"Nat. Protoc."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109640_b0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109640_b0115","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lungcan.2026.109640_b0120","article-title":"Enhanced recovery of CD9-positive extracellular vesicles from human specimens by chelating reagent","author":"Kurimoto","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","article-title":"MUC1-C Induces PD-L1 and Immune Evasion in Triple-negative Breast Cancer","volume":"78","author":"Maeda","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109640_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122230","article-title":"Targeting GAS6\/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer","volume":"335","author":"Kim","year":"2023","journal-title":"Life Sci."},{"issue":"24","key":"10.1016\/j.lungcan.2026.109640_b0135","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1158\/1078-0432.CCR-25-1098","article-title":"Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC","volume":"31","author":"Llerena","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0140","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109640_b0145","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1007\/s00432-022-04250-4","article-title":"Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer","volume":"149","author":"Zhao","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109640_b0150","article-title":"Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer","volume":"15(699):eadh8005","author":"Herzog","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109640_b0155","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109640_b0160","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109640_b0165","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109640_b0170","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 are Required for Antitumor Immune responses following Immune Checkpoint Blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109640_b0175","article-title":"Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response","volume":"5","author":"Gu\u00e9gan","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109640_b0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"issue":"7693","key":"10.1016\/j.lungcan.2026.109640_b0185","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109640_b0190","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","article-title":"Fibroblasts in cancer: Unity in heterogeneity","volume":"186","author":"Chhabra","year":"2023","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109640_b0195","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109640_b0200","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-Cell Analysis reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0205","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1038\/s41598-017-06922-5","article-title":"Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis","volume":"7","author":"Schliekelman","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0210","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T Cells to protect tumour cells","volume":"9","author":"Lakins","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0215","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","article-title":"Cancer-associated fibroblast classification in single-cell and spatial proteomics data","volume":"14","author":"Cords","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109640_b0220","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ccell.2024.08.011","article-title":"Classifying cancer-associated fibroblasts-the good, the bad, and the target","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"issue":"6669","key":"10.1016\/j.lungcan.2026.109640_b0225","first-page":"795","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A","volume":"391","author":"Braud","year":"1998","journal-title":"B and c. Nature."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109640_b0230","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1158\/2326-6066.CIR-18-0885","article-title":"Enriched HLA-E and CD94\/NKG2A Interaction Limits Antitumor CD8(+) Tumor-Infiltrating T Lymphocyte responses","volume":"7","author":"Abd Hamid","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"van Hall","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/187152209788009797","article-title":"Opposing Gatekeepers of Apical Sterol Transport: Niemann-pick C1-like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5\/ABCG8)","volume":"9","author":"Brown","year":"2009","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem."},{"issue":"7\u20138","key":"10.1016\/j.lungcan.2026.109640_b0245","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/00498250802007930","article-title":"Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review","volume":"38","author":"Kidambi","year":"2008","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol Induces CD8(+) T Cell Exhaustion in the Tumor Microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109640_b0255","doi-asserted-by":"crossref","first-page":"10695","DOI":"10.1093\/nar\/gkac817","article-title":"Human NOP2\/NSUN1 regulates ribosome biogenesis through non-catalytic complex formation with box C\/D snoRNPs","volume":"50","author":"Liao","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109640_b0260","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41419-024-06899-w","article-title":"NOP2 facilitates EZH2-mediated epithelial-mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109640_b0265","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35813","article-title":"Overall Survival among patients with De Novo Stage IV Metastatic and distant Metastatic Recurrent Non-Small Cell Lung Cancer","volume":"6","author":"Su","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0270","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-023-10950-y","article-title":"Survival differences between patients with de novo and relapsed\/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements","volume":"23","author":"Oh","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109640_b0275","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12951-021-00987-1","article-title":"Tetraspanins are unevenly distributed across single extracellular vesicles and bias sensitivity to multiplexed cancer biomarkers","volume":"19","author":"Mizenko","year":"2021","journal-title":"J Nanobiotechnology."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109640_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12213","article-title":"Tetraspanins distinguish separate extracellular vesicle subpopulations in human serum and plasma - Contributions of platelet extracellular vesicles in plasma samples","volume":"11","author":"Karimi","year":"2022","journal-title":"J Extracell Vesicles."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:08:58Z","timestamp":1792037338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226007014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":56,"alternative-id":["S0169500226007014"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109640","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109640"}}